Irinotecan, TAS-102 Plus Bevacizumab as a Second-Line Therapy in mCRC Patients

Metastatic colorectal cancer (mCRC) is a type of cancer that starts in the colon or rectum and has spread to other parts of the body. This study is testing a new treatment combination for patients whose cancer has not responded to standard treatments. The treatment uses a medicine called irinotecan, along with TAS-102 (a pill), and bevacizumab (an intravenous infusion). Patients get these medicines every two weeks. Doctors will use scans to check if the treatment is helping to shrink the cancer.

To join this study, patients must be at least 18 years old, have certain blood test results, and not have other serious health problems. People can't participate if they are allergic to the study drugs, have certain types of cancer, or have had recent surgeries or infections.

• Study may last for several months with visits every 14 days.
• Patients will receive a combination of drugs, including pills and infusions.
• Potential risks include side effects from the drugs used in the study.